Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20174242 | 0.95 | KMT2A (0.34) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL20174717 | 0.92 | MEN1 (0.36) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL20174266 | 0.92 | CYP1A1 (0.35) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL20174258 | 0.91 | KMT2A (0.36) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL22326549 | 0.89 | PLA2G2A (0.31) | KMT2APLA2G2APLA2G4A | |
| SCHEMBL20174241 | 0.89 | KMT2A (0.36) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL20174227 | 0.88 | KMT2A (0.36) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL20174279 | 0.88 | MEN1 (0.36) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL20174265 | 0.88 | CYP1A1 (0.35) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL22326526 | 0.88 | CYP1A1 (0.35) | KDM4EMEN1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-11 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | KDM4E 3633/4885MEN1 611/4885ALDH1A1 33/4885 |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | KDM4E 3633/4885MEN1 611/4885ALDH1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.